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Abstract
Background: High blood pressure during acute stroke is associated with poorer stroke outcome. Previous trials
have failed to show benefit from lowering blood pressure but treatment may have been commenced too late to
be effective. The earliest that acute stroke treatments could be initiated is during contact with the emergency
medical services (paramedics). However, experience of pre-hospital clinical trials is limited and logistical challenges
are likely to be greater than for trials performed in other settings. We report the protocol for a pilot randomised
controlled trial of paramedic initiated blood pressure lowering treatment for hypertension in acute stroke.
Methods: Trial Design: Double blind parallel group external pilot randomised controlled trial.
Setting: Participant recruitment and initial treatment by North East Ambulance Service research trained paramedics
responding to the emergency call. Continued treatment in three study hospitals.
Participants: Target is recruitment of 60 adults with acute arm weakness due to suspected stroke (within 3 hours of
symptom onset) and hypertension (systolic BP>160 mmHg).
Intervention: Lisinopril 5-10 mg (intervention group), matched placebo (control group), daily for 7 days.
Randomisation: Study medication contained within identical pre-randomised “trial packs” carried by research
trained paramedics.
Outcomes: Study feasibility (recruitment rate, compliance with data collection) and clinical data to inform the
design of a definitive randomised controlled trial (blood pressure monitoring, National Institute of Health Stroke
Scale, Barthel ADL Index, Modified Rankin Scale, renal function).
Discussion: This pilot study is assessing the feasibility of a randomised controlled trial of paramedic initiated
lisinopril for hypertension early after the onset of acute stroke. The results will inform the design of a definitive RCT
to evaluate the effects of very early blood pressure lowering in acute stroke.
Trial Registration: EudraCT: 2010-019180-10
ClinicalTrials.gov: NCT01066572
ISRCTN: 54540667
Background
Systemic hypertension occurs commonly during acute
stroke and is associated with increased neurological
impairment, poor functional outcome and death [1,2].
Due to the simultaneous disruption of cerebral vascular
autoregulation that occurs in acute stroke, systemic
hypertension has a greater effect on cerebral blood flow
than normal [3]. This can lead to excessive cerebral
oedema during ischaemic stroke or haematoma expan-
sion after haemorrhage, both of which are associated
with greater neurological injury [4]. Low levels of blood
pressure may also be harmful, however, probably
because of cerebral hypoperfusion [5]. Observational
data supports a U-shaped relation between baseline sys-
tolic blood pressure and outcome. For every 10 mmHg
rise above 150 mmHg the risk of early death rises by
3.8% but for every 10 mmHg fall below 150 mmHg the
risk of early death rises by 17.9% [5].
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unclear. A Cochrane meta-analysis of interventions for
deliberately altering blood pressure in acute stroke
showed that significant reductions in blood pressure
readings were possible, but functional outcome and
death were not altered by any of the drugs used [6].
More recent acute blood pressure lowering trials have
also shown no benefit on survival or reduction in dis-
ability [7]. The explanations for this include that inter-
ventions to lower blood pressure do not influence
mechanisms of progressive cerebral injury, and that
trials have not been of sufficient size to detect a treat-
ment effect [6,8]. However ,ak e yr e a s o nm a yb et h a t
blood pressure lowering treatment was started too late
after stroke onset to be effective. Acute stroke treat-
ments are known to be time dependent due to the rapid
speed at which neuronal injury occurs following cerebral
hypoxia and oedema [9]. This has been very clearly
demonstrated by the pooled data from trials assessing
the effects of intravenous thrombolysis on acute ischae-
m i cs t r o k ew h e r ee v e r ym i n u t eo fd e l a yr e s u l t e di na
reduced chance of a better outcome until 4.5 - 6 hours
after symptom onset[10]. Current hospital based trials of
blood pressure lowering following cerebral haemorrhage
have recognised the importance of treatment timing and
are being performed with time windows of 6 hours or
less [11,12].
The earliest that patients suffering an acute stroke
could receive treatment or be invited to participate in a
clinical trial is during contact with the emergency medi-
cal services (paramedics). Such pre-hospital intervention
could result in an important reduction in time to treat-
ment which may influence stroke outcome. Although
pre-hospital clinical trials are not a new concept, few
have been conducted to date [13,14]. In terms of pre-
hospital stroke trials, experience is very limited with
only one trial in Los Angeles, the Field Administration
of Stroke Therapy - Magnesium (FASTMAG) trial,
which is currently examining the neuroprotective effect
of intravenous magnesium infusion [15].
Gaps in the evidence for pre-hospital care are well
recognised, and in the UK a number of national reviews
are currently driving the development of infrastructure
to support and enable research in this setting [14,16,17].
However, the lack of randomised controlled trials (RCT)
in the pre-hospital setting is also likely to be due to
greater logistical problems with their conduct. Whilst it
is accepted that RCTs in any setting are challenging to
perform, this is likely to be even more so in the pre-hos-
pital domain [18,19]. Procedures such as randomisation,
drug supplies and data collection are more difficult to
organise with a mobile workforce operating from ambu-
lances [18,19]. Emergency medical staff need to be
trained in trial processes and then have the confidence
to approach and recruit suitable patients [18,19]. In
addition, emergency medical staff must be willing to
participate in a trial which will usually involve duties
additional to routine service provision.
Where the logistics of a randomised controlled trial
are unclear, an external (rehearsal) pilot trial can be car-
ried out to inform the design of a definitive study
[20,21]. Pilot trials can be used to test protocol proce-
dures such as the consent process, randomisation
arrangements and data collection instruments. They can
also be used to determine the most appropriate primary
outcome measure, to estimate eligibility, recruitment
and retention rates, and to inform sample size calcula-
tions for a future definitive trial [20,21].
This paper describes the protocol for a pilot rando-
mised controlled trial of paramedic initiated lisinopril or
placebo for treatment of hypertension in acute stroke.
As the logistics of randomised controlled trials in the
pre-hospital settling are not well established, and an
acute stroke trial has particular challenges with mental
capacity, communication difficulties and swallowing
impairment, a pilot trial is necessary to inform the
future design of a definitive pre-hospital acute stroke
blood pressure lowering trial. Lisinopril has been chosen
as the antihypertensive agent as it has been demon-
strated to lower blood pressure after acute stroke, has a
good safety profile, and can be administered sublin-
gually. The recent Controlling Hypertension and Hypo-
tension Immediately Post Stroke (CHHIPS) trial
demonstrated the blood pressure lowering effect of lisi-
nopril in acute stroke including the tolerability and anti-
hypertensive effect of sublingually administered
lisinopril which was given to participants with dysphagia
[22]. Due to the high frequency of swallowing problems
during acute stroke, the first dose of study medication is
delivered sublingually in our pilot trial.
The Paramedic Initiated Lisinopril For Acute Stroke
Treatment (PIL-FAST) study follows current recom-
mendations for the design of pilot randomised con-
trolled trials [20,21].
Methods
Study aim
The aim of this study is to assess the feasibility of a
double blind parallel group randomised controlled trial
of paramedic initiated blood pressure lowering treat-
ment for patients with symptoms of recent stroke.
Primary objective
To demonstrate whether it is possible to enrol at least
four patients per month into the trial (from an ambu-
lance service covering a population of 500,000).
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￿ To report the proportion of suspected acute stroke
patients admitted to research sites during the trial dura-
tion who fulfilled the study eligibility criteria.
￿ To report the proportion of study eligible patients
attended by a research trained paramedic.
￿ To report the proportion of study eligible patients
enrolled into the study by a research trained paramedic.
￿ To report the proportion of study eligible patients
approached about the research study but not enrolled,
and to report reasons for non-enrolment where possible.
￿ To report the proportion of study eligible patients
not approached about the research study, and to report
reasons for non-approach where possible.
￿ To determine the additional time spent on scene by
research trained paramedics to enrol a participant into
the study.
￿ To report paramedic compliance with study data
collection.
￿ To report hospital staff compliance with study medi-
cation administration and data collection.
￿ To report the proportion of study participants with
confirmed stroke who complete seven days of study
medication.
￿ To collect and report completeness and summary
statistics on clinical data to inform the design of a defi-
nitive multicentre randomised controlled trial:
- change in blood pressure in intervention and con-
trol groups for 7 days post stroke
- change in neurological score (National Institute of
Health Stroke Scale [23]) in intervention and control
groups at 3 and 7 days post stroke
- dependency score (Barthel Activities of Daily Liv-
ing (ADL) Index [24], Modified Rankin Scale [25]) in
intervention and control groups at 7 days post stroke
- change in renal function in intervention and con-
trol groups at 7 days post stroke
- mortality in intervention and control groups at 7
days post stroke
￿ To report adverse events in control and intervention
groups during the study.
Study design
The study is a double blind parallel group randomised
controlled external (rehearsal) pilot trial assessing the
feasibility of paramedic initiated lisinopril for acute
stroke. Figure 1 outlines the study method.
Study setting
The study is being undertaken by the North East Ambu-
lance Service NHS Trust (NEAS), Newcastle upon Tyne
Hospitals NHS Foundation Trust (Royal Victoria
Infirmary) and Northumbria Healthcare NHS Founda-
tion Trust (two sites, North Tyneside General Hospital
and Wansbeck General Hospital). The study is initiated
in the community by NEAS research trained parame-
dics, including administration of the first dose of study
medication. The NEAS workforce is divided into geogra-
phical regions and the study is active in the North of
Tyne division where patients are transported to the
Newcastle or Northumbria hospitals which are taking
part in the pilot trial. The North of Tyne division covers
a population of approximately 500,000 and admits
around 1200 patients with suspected stroke per year.
Study population
Adults with suspected acute stroke presenting to NEAS
North of Tyne research trained paramedics who fulfil
the following criteria are eligible:
Adults with suspected hyperacute stroke 
and elevated blood pressure identified by 
research trained paramedics. 
Consent obtained pre-hospital by research 
trained paramedics. 
Randomisation to lisinopril or placebo by 
pre-randomised ‘trial pack’ carried by 
research trained paramedic. 
1
st dose of medication administered in 
ambulance.
Intervention 
Lisinopril 5-10mg  
daily for 7 days 
Control
Matched placebo  
daily for 7 days 
Blood pressure monitoring  
Day 3
Blood pressure measurement 
National Institute of Health Stroke Scale 
Day 7
Blood pressure measurement 
National Institute of Health Stroke Scale 
Barthel ADL index 
Modified Rankin Scale 
Renal function 
Mortality 
Transfer to hospital.  
Handover and review by hospital clinical and 
research staff. 
Figure 1 Study method.
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￿ Adults ≥ 40 years old
￿ New unilateral arm weakness thought to be due to
acute stroke within 3 hours of symptom onset
￿ Hypertension as defined by systolic BP >160 mm Hg
on two consecutive seated or lying readings taken 5 - 10
minutes apart
￿ Conscious (eyes open spontaneously i.e. “A” on
Alert, Voice, Pain, Unresponsive (AVPU) scale)
￿ Patient being transported to a PIL-FAST trial site
(i.e. Royal Victoria Infirmary, North Tyneside General
Hospital or Wansbeck General Hospital)
￿ Verbal consent obtained from participant or next of
kin
Exclusion criteria
￿ Age < 40 years
￿ Females who are pregnant, lactating or at risk of
pregnancy (i.e. who are not surgically sterile or at least 1
year post last menstrual period). Females < 56 years of
age consented by a relative will be excluded as men-
strual history may be unknown.
￿ Any presentation of suspected stroke without unilat-
eral arm weakness
￿ Cannot establish that stroke onset time (i.e. when
patient was last seen well without symptoms) was within
the last 3 hours
￿ Systolic BP < 160 mm Hg
￿ Reduced level of consciousness (below “A” on AVPU
scale)
￿ Patient not being transported to PIL-FAST trial site
￿ Absence of participant or next of kin consent
￿ Known to be taking Angiotensin Converting Enzyme
(ACE) inhibitor or Angiotensin II Receptor Blocker
medication already
￿ Known sensitivity to lisinopril or other ACE-inhibi-
tor medication
￿ Pulse > 120 beats per minute
￿ Seizure activity in this illness episode (witnessed or
history)
￿ Hypoglycaemia (blood glucose < 3.5 mmols/l)
￿ Cannot walk independently prior to stroke (walking
stick / frame is allowed)
￿ Obvious understanding or memory problems when
next of kin is absent
￿ Significant head trauma or brain surgery in the last 3
months
￿ Known renal failure
￿ Known liver failure (or currently jaundiced)
￿ Uncontrolled heart failure (breathlessness at rest)
￿ Receiving palliative care for known malignancy
￿ Currently enrolled in a clinical trial assessing a study
drug
Case ascertainment
Potential participants are identified by research trained
paramedics using routinely collected clinical data.
Screening, recruitment and consent
Assessment of study eligibility, invitation to participate
in the study and consent is undertaken in the pre-hospi-
tal setting by research trained paramedics. Confirmation
of suitability to continue study medication and provision
of more detailed information is performed by the hospi-
tal stroke research team within 18 hours of admission to
hospital.
Assessment and consent in the pre-hospital setting
The routine clinical assessment of patients with acute
stroke by paramedics (i.e. symptoms and signs of stroke,
physiological observations, previous medical history, cur-
rent medications and drug sensitivities) provides the
information needed to determine whether a patient ful-
fils the study inclusion and exclusion criteria. Confirma-
tion of fulfilment of the eligibility criteria is recorded on
the study case record form (CRF) following consent to
enter the study.
If a potential participant meets the inclusion cri-
t e r i a ,as i m p l ee x p l a n a t i o no ft h es t u d yi sp r o v i d e d
verbally by the attending research trained paramedic
as follows:
￿ Your symptoms suggest you have had a stroke.
￿ Your blood pressure is high.
￿ We are working with doctors at Newcastle Univer-
sity to find out if it is possible to use a blood pressure
lowering treatment before patients reach hospital.
￿ In some people this might improve recovery after
stroke, but it is not proven.
￿ Would you be willing to take part in a study to help?
￿ This means receiving a small dose of a blood pres-
sure lowering tablet or an identical “dummy” tablet
before reaching hospital. The type of tablet people
receive is decided by chance.
￿ You will be offered one or two of these extra tablets
for the next seven days.
￿ If you agree to take part then you will be told more
about the study at hospital and given the option to pull
out if you change your mind.
￿ Your treatment and care will not be affected if you
decide not to take part.
Following this explanation the research trained para-
medic assesses the understanding of the potential parti-
cipant by asking three questions as below.
Can I check you understood what I said about the
study?
￿ What do we think is wrong with you at the
moment? [answer: stroke]
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high]
￿ What will you receive if you do help with the study?
[answer: tablet]
An opportunity to ask questions is then provided. The
research paramedic asks “Do you have any questions
about the study?” The patient is then asked to provide
verbal confirmation that they are happy to take part.
The consent process takes approximately three to five
minutes. A longer consent process would delay transfer
to hospital. Verbal confirmation of consent is recorded
on the paramedic signed CRF. Following verbal consent,
the patient enters the study and receives the first dose
of study medication.
If a potential participant meets the inclusion criteria
but does not appear to have mental capacity during the
consent process or during the routine clinical assess-
ment, it is possible for the next of kin or other close
relative present at the time to act as a personal legal
representative and provide consent on the basis of their
understanding of the wishes of the patient. Verbal con-
sent from the relative is recorded on the CRF.
If the paramedic is uncertain whether the patient
meets the inclusion/exclusion criteria, or whether they
have demonstrated sufficient understanding of the trial
during the first stage of consent, they are able to contact
the stroke physician on call for the locality for advice by
mobile phone.
Provision of further study information and confirmation of
appropriateness to continue study medication in the
hospital setting
A more detailed study explanation and a patient infor-
mation sheet is provided to the participant and/or next
of kin/close relative by a member of the hospital stroke
research team within 18 hours of admission to hospital.
Confirmation of consent is obtained in writing from
either the participant or next of kin/close relative by the
admitting stroke physician. If the participant has mental
capacity but is unable to sign the consent form (e.g.
because of weakness of the dominant hand following
stroke), consent may be confirmed orally in the presence
of an independent witness (an individual not otherwise
involved in the trial) who will sign the consent form on
behalf of the participant. The participant (or next of
kin/close relative) is free to withdraw from the study if
unhappy to continue following this more detailed expla-
nation. All participants who withdraw from the trial
after receiving study medication are monitored for
adverse events for seven days.
Following the availability of further clinical data, suit-
ability to continue study medication is reviewed within
18 hours of admission by the hospital stroke research
team. The following reasons make it inappropriate to
continue with study medication:
￿ Diagnosis is found NOT to be stroke
￿ Revised stroke onset time was not within 3 hours of
presentation to paramedics
￿ Female found to be at risk of pregnancy
￿ Documented to be taking ACE inhibitor or Angio-
tensin II receptor blocker
￿ Documented to be sensitive to lisinopril or other
ACE-inhibitor medication
￿ Found to be in renal failure (Cr > 200)
￿ Found to have liver failure or to be jaundiced
￿ Found to have uncontrolled heart failure
￿ Found to be receiving palliative care for malignancy
￿ Found to have significant head trauma or had brain
surgery in the last 3 months
￿ Found to be already enrolled in a clinical trial asses-
sing a study drug
Reasons for discontinuation of study medication are
recorded on the CRF. All participants continue to be
followed up for the duration of the study. It is possible
that one or more of the above reasons for discontinua-
tion of study medication will only become available after
18 hours; in this event, study medication will be discon-
tinued at this later time.
Design of recruitment and consent
The processes for recruitment and consent as described
have been designed to enable this research to take place
in the emergency setting. The consent process in emer-
gency research should not interfere with clinical care (i.
e. in this case lead to a lengthy delay in transfer to an
a c u t es t r o k eu n i t )b u ts h o u l d“take due account of the
views, however expressed, by the person being treated
or by their family or friends who are with them” [26]. If
a traditional consent process is not undertaken at the
time of the emergency, the recommendation is that: “as
soon as the emergency is over, arrangements must be
made to seek consent in the usual manner, or to seek
advice from a consultee on the continued participation
of the person who lacks capacity in the study” [26].
As stroke can create impairments which interfere with
communication and mental capacity, the consent pro-
cess incorporates a simple capacity assessment and the
views of relatives will be sought about trial participation
where mental capacity is impaired. Relative consent has
been used in other trials of emergency neurological con-
ditions (Corticosteroid Randomisation After Significant
Head Injury (CRASH) trial which examined the role of
steroids in the emergency treatment of acute head injury
[27] and the National Institute of Neurological Disor-
ders and Stroke (NINDS) trial which evaluated intrave-
nous thrombolysis for stroke [28]). Relative consent is
also used in current randomised controlled trials of
emergency stroke treatments including the 3
rd Interna-
tional Stroke Trial [29] and Stroke Oxygen Study [30].
We believe the design of our consent process is unique
Shaw et al. Trials 2011, 12:152
http://www.trialsjournal.com/content/12/1/152
Page 5 of 11as we have developed a standardised approach for non
medically qualified ambulance paramedics to assess
understanding of the trial to support consent in the pre-
hospital setting. Exclusion of patients with communica-
tion or mental incapacity would mean exclusion of
patients with more disabling strokes who may have the
most to gain from treatment.
Study medication
Participants receive lisinopril (5-10 mg) or matched pla-
cebo daily for 7 days. Lisinopril is a licenced medication
for the treatment of hypertension but by initiation
within the hyperacute phase of stroke it is used outside
of the specific indications in the current licence and is
being treated as an investigational medicinal product
(IMP) in this trial.
Lisinopril and matched placebo tablets are blister
packaged and boxed (16 tablets per box). Boxes are
identical and each carries a unique study number linked
to the randomisation code. Modepharma, a clinical trial
supplies company, supplied the boxed lisinopril and
matched placebo which were obtained from Haupt
Pharma Wuelfing (Germany).
The first participant treatment is 5 mg (1 tablet) admi-
nistered by a research trained paramedic following study
entry. As lisinopril (and placebo) is not a routine pre-
hospital drug, a trial specific Patient Group Directive
(PGD) was developed and subsequently approved by the
North East Ambulance Service NHS Trust to enable
research trained paramedics to administer trial medica-
tion. Due to the high frequency of swallowing problems
during acute stroke, the first dose is delivered sublin-
gually. The 5 mg tablet (lisinopril or matched placebo)
is crushed in a syringe crusher with 3 - 5 mls of water
and then administered under the tongue. The assess-
ment of swallowing safety cannot be done by parame-
dics and swallowing safety may change rapidly.
Following arrival of a participant at hospital, review of
the appropriateness to continue study medication and
provision of further information (as above), the stroke
physician makes a decision about dose titration. Three
blood pressure readings are taken and if the systolic
blood pressure (SBP) remains > 150 mmHg, a second
dose of lisinopril or matched placebo (5 mg) is adminis-
tered. Route of administration is either oral, sublingual
or via nasogastric tube, dependent on swallow safety,
which is assessed as part of routine care after admission.
If the SBP is < 150 mmHg a second dose is NOT admi-
n i s t e r e d .Ad a i l yd o s eo f5m g( o n et a b l e t )i sg i v e ni f
dose escalation has not been necessary and 10 mg (two
tablets, as a single daily dose) if dose escalation was per-
formed. Route of administration is either oral, sublingual
or via nasogastric tube, dependent on swallow safety
which may change over the course of the study.
If already prescribed pre-stroke, participants continue
on their usual blood pressure lowering medication as
well as the trial medication. Without thrombolysis, if
systolic blood pressure remains below 200 mmHg dur-
ing the first 7 days then no additional blood pressure
lowering medication will be introduced until after the
day 7 assessment, unless the clinical team judge it is
important for the blood pressure to be lowered more
urgently according to the condition of the patient. If the
systolic blood pressure exceeds 200 mmHg within the
trial intervention period, the clinical team will decide on
additional blood pressure lowering treatment. If patients
in the trial receive thrombolysis and their blood pres-
sure rises above 185 mmHg then clinical treatment pro-
tocols dictate that additional medication will be started
to reduce blood pressure below this level for 24 hours,
after which clinical judgement will determine whether
additional new blood pressure lowering measures are
required in addition to the trial medication.
If a participant develops clinically significant hypoten-
sion (i.e. symptomatic < 120 mmHg), trial medication
will be withheld and all pre-trial blood pressure lower-
ing medications being administered will be reviewed. If
blood pressure increases to >150 mmHg trial drugs will
be reintroduced at the 5 mg dose. All medication
changes are noted on the CRF. Daily dosage of study
medication and compliance with treatment is also
recorded on the CRF.
If a participant is discharged from hospital before
seven days, they will take the remaining tablets at home.
Following completion of the study, the stroke physician
will decide on any further appropriate blood pressure
lowering treatment required by the patient on the basis
of clinical assessment.
The PIL-FAST ‘trial pack’
In order to enable access to study medication and the
necessary administration equipment in the pre-hospital
setting, boxes of lisinopril and matched placebo, along
with other study materials, have been secondarily pack-
aged into a ‘trial pack’. The trial pack contains the para-
medic research paperwork, study medication, a syringe
crusher, a 5 ml syringe and 5 ml vial of water. Each
pack carries a unique study number which matches the
medication box number (linked to the randomisation
code). Packaging of trial packs was carried out by the
Newcastle upon Tyne Hospitals Pharmacy Production
Unit.
The provision of trial packs to research trained para-
medics mirrors the provision of routine ambulance drug
supplies to the North East Ambulance Service which are
provided by Lloydspharmacy, a community pharmacy, in
weekly deliveries to ambulance stations. Once packaged
by the Newcastle upon Tyne Hospitals Pharmacy
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local Lloydspharmacy in Gateshead who are storing and
delivering the packs to participating North of Tyne
ambulance stations. Lloydspharmacy delivery staff place
packs in the ambulance station drug rooms and replen-
ish to meet a minimum stock supply on their weekly
visit to restock routine drug supplies.
A trial pack is collected by each research trained para-
medic, taken into their ambulance service vehicle and
carried on their emergency shift. If the pack is unused
at the end of the shift, it is stored in the paramedic’s
individual secure locker until their next shift. This
approach is being employed due to the logistics of drug
storage on ambulance service vehicles and because the
vehicles will not always carry a research trained parame-
dic. Second and subsequent packs are collected once the
first pack has been used. Packs are opened after an eligi-
ble patient gives consent to take part in the trial and
contents accompany the participant to hospital.
In addition to the contents listed above, 20% of the
trial packs also contain a small temperature monitoring
device. This is because ambulance service vehicles do
not contain temperature controlled storage spaces and
trial medication should not be stored above 25°C. Tem-
perature monitoring is also being performed in a sample
of ambulance station storage areas which similarly are
not routinely temperature controlled.
Paramedic training
Paramedics taking part in the study are volunteers from
the NEAS North of Tyne division. In order to partici-
pate, they must have attended a training day which cov-
ered the principles of Good Clinical Practice (GCP),
stroke recognition and trial eligibility assessment, the
trial consent process and other trial procedures. In addi-
tion, all research trained paramedics have been issued
with a small laminated booklet, designed to be carried
on emergency shifts, which details inclusion and exclu-
sion criteria, the consent script and emergency contact
numbers.
Randomisation
Treatment allocation is according to the trial pack car-
ried by the recruiting paramedic. The trial packs carry
unique study numbers identical to the numbers on the
boxes of lisinopril and matched placebo contained
within. The numbers are according to a master rando-
misation list created by an independent statistician.
Intervention and control allocations are in 1:1 ratio.
Blinding
Participants, clinicians (paramedics, investigators, out-
come assessors) and other trial staff are blinded to
treatment allocation. Lisinopril and placebo tablets are
identical in appearance and packing. In the event of
an emergency (as confirmed by the local site investiga-
tor, chief investigator or emergency doctor if investiga-
tors unavailable), the on-call pharmacist at the trial
pharmacy can be contacted to reveal treatment
allocation.
The integrity of blinding is checked at the final parti-
cipant assessment. The participant is asked if they
believe they received lisinopril or placebo. The assessor
is also asked to record the treatment that they believe
the participant to have received.
Baseline data
In addition to the baseline eligibility data collected by
research trained paramedics, the following are collected
from routine records by a member of the hospital stroke
research team following arrival of the participant at hos-
pital: place of residence, past medical history, medica-
tion prior to admission, stroke type, brain imaging
result, electrocardiogram result (rate, rhythm, voltage
criteria for left ventricular hypertrophy (LVH)), renal
function (urea and creatinine) on admission.
The following assessments are also performed within
18 hours of admission to hospital:
￿ Pre-stroke Barthel ADL Index score [24]
￿ Pre-stroke Modified Rankin Scale score [25]
￿ National Institute of Health Stroke Scale score [23]
Furthermore, at the hospitals taking part in this
research study, the stroke research teams routinely
screen the records of all patients admitted with a diag-
nosis of suspected acute stroke. Data from this screen is
being used to identify all patients who fulfilled the study
eligibility criteria and those that were transported to
hospital by a research trained paramedic. For patients
transported to hospital by a research trained paramedic
and study eligible but not enrolled, paramedic routine
clinical records are examined and any details about
study screening or approach recorded if available.
In order to assess the additional time spent on scene
by paramedics enrolling trial participants, time from
arrival on scene to hospital door is obtained for all
stroke admissions to the research hospitals from NEAS
data records.
Outcome assessments
Outcome data is collected from (i) routine clinical
records and (ii) specific research assessments, by a
member of the hospital stroke research team.
(i) Blood pressure during the first 48 hours following
study entry is transcribed from routine clinical records
onto the study CRF. Blood pressure at hospital admis-
sion, and at 4, 24 and 48 hours after admission is
recorded (blood pressure is also recorded at the study
medication dosage review, as above).
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3 after study entry and (b) day 7 (+/- 1 day) after study
entry.
(a) On day 3 after study entry the following assess-
ments are performed:
￿ Blood pressure (3 readings)
￿ National Institute of Health Stroke Scale
(b) On day 7 (+/- 1 day) after study entry the follow-
ing assessments are performed:
￿ Blood pressure (3 readings)
￿ National Institute of Health Stroke Scale
￿ Barthel ADL Index
￿ Modified Rankin Scale
￿ Blood test for renal function, (urea, creatinine)
If a participant is discharged before day 3 or 7 follow-
ing study entry, they will be asked to attend the outpati-
ent department for data collection.
The study schedule is shown in Table 1.
Study withdrawal
No specific study withdrawal criteria have been pre-set.
Participants may withdraw from the study at any time
for any reason. Should a patient decide to withdraw
from the study, a reason will be sought (to allow the
study team to assess likely barriers to participation and
retention) but patients can chose to withdraw without
providing an explanation. Participants who chose to
withdraw are monitored for adverse events for seven
days after initiation of study medication. Patients
wishing to withdraw prematurely from study medication
are asked if they would be willing to continue with fol-
low-up assessments as per the study schedule.
Investigators may also withdraw participants from the
study at any time if they feel it is no longer in their
interest to continue, for example, because of intercur-
rent illness or adverse events. Withdrawn participants
are not replaced.
Pharmacovigilance
The safety of lisinopril 5-10 mg in acute stroke will be
evaluated by examining the occurrence of all adverse
events as defined by the Medicines for Human Use
(Clinical Trials) Regulations [31].
For serious adverse events (SAE), relationship to treat-
ment (causality) and expectedness is determined by the
local site investigator. Any queries will be discussed
with the Chief Investigator. Excepting common and
anticipated stroke complications (pneumonia, urinary
tract infection, seizure, headache, deep vein thrombosis,
pulmonary embolism), all SAEs will be reported to the
co-ordinating centre immediately (within 24 hours) to
comply with the Medicines for Human Use (Clinical
Trials) Regulations [31]. Anticipated stroke complica-
tions need not be reported within 24 hours.
Table 1 Study schedule
Day
1
Day
2
Day
3
Day
4
Day
5
Day
6
Day
7
Eligibility assessed by paramedic from routine clinical data x
Study discussed and verbal informed consent/assent obtained by paramedic x
Randomisation x
Further study information provided and written informed consent/assent obtained by hospital
research team
x
Appropriateness to continue study medication reviewed by hospital team x
Review of medical records to collect baseline stroke details and medical history X
Blood pressure measurements x x x x
National Institute of Health Stroke Scale x x x
Barthel ADL Index
(pre-stroke)
x
Barthel ADL Index
(post-stroke)
x
Modified Rankin Scale
(pre-stroke)
x
Modified Rankin Scale
(post-stroke)
x
Blood test for renal function x
Review of medical records to record concomitant blood pressure medications x
Treatment with study medication xxxxxxx
Review of study medication dosage x
Adverse Events xxxxxxx
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Agency (MHRA) and ethics committee will be notified
of all suspected unexpected serious adverse reactions
(SUSAR) according to the following timelines in line
with the Medicines for Human Use (Clinical Trials)
Regulations: fatal and life threatening within 7 days of
notification, non life threatening within 15 days. SUS-
ARs will also be notified to all trial sites.
For non serious adverse events, local site investigators
will determine relationship to treatment and data will be
processed with routine trial data.
Pregnancies
If a pregnancy is confirmed in a female participant dur-
ing her participation in the trial, the study drug will be
discontinued immediately. The pregnancy will be fol-
lowed up to determine the outcome. Additional follow-
up will no longer be required once the newborn is
determined to be healthy.
Statistical analysis
As this is a pilot study, the statistical analysis will be
descriptive in nature, providing estimates of key trial
parameters and to inform power calculations for a
future definitive trial. Formal statistical comparisons
between randomisation groups will not be undertaken.
Sample size calculation
As this is a pilot study, a formal sample size calculation
has not been carried out. We aim to recruit and rando-
mise 60 participants; collecting data on 30 patients per
randomisation group is acceptable for calculating sample
sizes [20]. We believe that approximately 200 patients
per year who fulfil the study eligibility criteria will pre-
sent to NEAS within the research boundaries.
Ethical arrangements and research governance
The study is being conducted in accordance with the
principles of Good Clinical Practice (GCP) [32], the
Medicines for Human Use (Clinical Trials) Regulations
[31] and the Research Governance Framework for
Health and Social Care [33]. Ethical, NHS Trust and
MHRA approvals have been obtained. The study spon-
sor is Newcastle upon Tyne Hospitals NHS Foundation
Trust.
A Data Monitoring and Ethics Committee (DMEC)
and Trial Steering Committee (TSC) have been
convened.
Current study status
The study commenced on 29
th October 2010. Seventy
six paramedics have received PIL-FAST training.
Recruitment will be until end of December 2011. Results
will be submitted for publication in 2012.
Discussion
Systemic hypertension in acute stroke is associated with
poorer stroke outcome [1,2], but optimal treatment of
hypertension early after stroke is unclear [6]. Previous
randomised controlled trials of blood pressure lowering
agents may have failed to show improved functional
outcome due to treatment being administered too late
after stroke to be effective. The earliest time after stroke
that treatment could be initiated is during contact with
the emergency medical services (paramedics).
This paper describes a protocol for a pilot randomised
controlled trial of paramedic initiated lisinopril for
hypertension in acute stroke. Pilot RCTs are important
to perform when the logistics of a large scale trial are
unclear [20,21]. Experience of pre-hospital RCTs, espe-
cially pre-hospital stroke trials, is very limited, making a
pilot study a necessary and important step of a definitive
evaluation.
This pilot study will inform the design of a large
multicentre randomised controlled trial to evaluate
very early blood pressure lowering in acute stroke. We
will determine if paramedic recruitment to an acute
stroke trial is feasible along with the estimated recruit-
ment rate that could be achieved. We are testing a
novel consent process, and method for randomisation,
availability of trial medication and supporting equip-
ment (the trial pack). We will also review the comple-
teness of paramedic and hospital staff data collection,
both of which are important for a definitive study. In
addition, we hope to capture any unanticipated proto-
col logistical issues integral to the success of a future
large scale RCT.
If the feasibility of this pre-hospital acute stroke trial is
demonstrated, it will allow the conduct of a definitive
RCT to evaluate the effects of very early blood pressure
lowering in acute stroke. It will also pave the way for
evaluation of other potential paramedic initiated treat-
ments where very early intervention may improve
outcome.
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